Voriconazole or Amphotericin B as Primary Therapy Yields Distinct Early Serum Galactomannan Trends Related to Outcomes in Invasive Aspergillosis

• Louis Yi Ann Chai ,

  * E-mail: chailouis@hotmail.com

  Affiliations Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, the Netherlands, Division of Infectious Diseases, University Medicine Cluster, National University Health System, Singapore, Singapore

  ⨯
• Bart Jan Kullberg,

  Affiliations Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, the Netherlands

  ⨯
• Arul Earnest,

  Affiliation Center for Quantitative Medicine, Duke-NUS Graduate Medical School, Singapore, Singapore

  ⨯
• Elizabeth M. Johnson,

  Affiliation Mycology Reference Laboratory, Health Protection Agency, Bristol, United Kingdom

  ⨯
• Steven Teerenstra,

  Affiliation Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands

  ⨯
• Alieke G. Vonk,

  Affiliation Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands

  ⨯
• Haran T. Schlamm,

  Affiliation Pfizer Global Research and Development, New York, New York, United States of America

  ⨯
• Raoul Herbrecht,

  Affiliation Department of Oncology and Hematology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

  ⨯
• Mihai G. Netea,

  Affiliations Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, the Netherlands

  ⨯
• Peter F. Troke

  Affiliation The Old Court, Broadstairs, Kent, United Kingdom

  ⨯